



NDA 022155/S-29

**SUPPLEMENT APPROVAL**

Kenvue Brands LLC  
Attention: Jennifer D. Norman, RPh  
Director, Regulatory Affairs  
7050 Camp Hill Road  
Mail Stop III  
Fort Washington, PA 19034-2299

Dear Jennifer Norman:

Please refer to your supplemental new drug application (sNDA) dated and received August 28, 2025, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zyrtec Allergy (cetirizine hydrochloride) oral solution, 1 mg per mL.

This "Prior Approval" supplemental new drug application provides for an additional flavor, Cooling Tropical Breeze, which includes bottle labels and carton labels for both 4 fl oz and 8 fl oz products.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**LABELING**

Submit final printed labeling (FPL), no more than 30 days after they are printed. The FPL must be the enclosed labeling described in the table below. The Drug Facts label (DFL) for both the outer carton and bottle labeling must be consistent with the DFL submitted on December 16, 2025.

<b>Submitted Draft Labeling</b>	<b>Date</b>
4 oz outer carton	11/06/2025
4 oz bottle	11/06/2025
8 oz outer carton	11/06/2025
8 oz bottle	11/06/2025
Drug Facts Label	12/16/2025

The FPL should be submitted electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*.<sup>1</sup> For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 022155/S-029**.” Approval of this submission by FDA is not required before the labeling is used.

Remove the “NEW” flag 6 months after marketing.

## **DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.<sup>2</sup> Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

## **PATENT LISTING REQUIREMENTS**

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

---

<sup>1</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

<sup>2</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

If you have questions, contact Tam Dinh, PharmD, regulatory project manager, at 240-402-6284 or [Tam.Dinh@fda.hhs.gov](mailto:Tam.Dinh@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Nushin Todd, MD, PhD  
Director  
Division of Nonprescription Drugs I  
Office of Nonprescription Drugs  
Office of New Drugs  
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Carton and Container Labeling

---

**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**

---

/s/

---

NUSHIN F TODD  
12/24/2025 09:07:53 PM